MaxCyte and Kamau Therapeutics sign platform license agreement [Yahoo! Finance]
MaxCyte, Inc. (MXCT)
Company Research
Source: Yahoo! Finance
In exchange, MaxCyte will receive annual licensing fees along with programme-related revenue. Kamau's approach to therapy development involves high-efficiency targeted gene integration, to build a new class of treatments to cure a range of serious and life-threatening diseases such as sickle cell disease (SCD). Its platform, based on HDR editing, builds upon first-generation CRISPR-Cas9 technology. This technique not only cuts DNA but also provides a DNA template. MaxCyte CEO and president Maher Masoud stated: “Bringing this groundbreaking gene therapy research into the clinic requires a robust manufacturing process and the ability to scale. “By partnering with us, Kamau gains access to our commercially validated Flow Electroporation technology as well as technical, regulatory and scientific support. This enables them to optimise their clinical manufacturing process, mitigate risks and expedite the progression of their lead product candidate through clinical phases to deliver
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- This MaxCyte Insider Increased Their Holding In The Last Year [Yahoo! Finance]Yahoo! Finance
- MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsGlobeNewswire
- MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... [Yahoo! Finance]Yahoo! Finance
- MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance [Yahoo! Finance]Yahoo! Finance
MXCT
Earnings
- 11/6/24 - Beat
MXCT
Sec Filings
- 11/13/24 - Form SC
- 11/8/24 - Form SC
- 11/6/24 - Form 10-Q
- MXCT's page on the SEC website